Please use this identifier to cite or link to this item:
Title: Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.
Authors: González-López, Tomás J
Alvarez-Román, María T
Pascual, Cristina
Sánchez-González, Blanca
Fernández-Fuentes, Fernando
Pérez-Rus, Gloria
Hernández-Rivas, José A
Bernat, Silvia
Bastida, José M
Martínez-Badas, María P
Martínez-Robles, Violeta
Soto, Inmaculada
Olivera, Pavel
Bolaños, Estefanía
Alonso, Rafael
Entrena, Laura
Gómez-Nuñez, Marta
Alonso, Arancha
Yera Cobo, María
Caparrós, Isabel
Tenorio, María
Arrieta-Cerdán, Esther
Lopez-Ansoar, Elsa
García-Frade, Javier
González-Porras, José R
Keywords: efficacy;eltrombopag;immune thrombocytopenia;safety;thrombopoietin
metadata.dc.subject.mesh: Adult
Autoimmune Diseases
Drug Administration Schedule
Lymphoproliferative Disorders
Middle Aged
Platelet Count
Purpura, Thrombocytopenic, Idiopathic
Receptors, Thrombopoietin
Retrospective Studies
Virus Diseases
Issue Date: 1-Jun-2017
Abstract: Eltrombopag is a second-line treatment in primary immune thrombocytopenia (ITP). However, its role in secondary ITP is unknown. We evaluated the efficacy and safety of eltrombopag in secondary ITP in daily clinical practice. Eighty-seven secondary ITP patients (46 with ITP secondary to autoimmune syndromes, 23 with ITP secondary to a neoplastic disease subtype: lymphoproliferative disorders [LPDs] and 18 with ITP secondary to viral infections) who had been treated with eltrombopag were retrospectively evaluated. Forty-four patients (38%) had a platelet response, including 40 (35%) with complete responses. Median time to platelet response was 15 days (95% confidence interval, 7-28 days), and was longer in the LPD-ITP group. Platelet response rate was significantly lower in the LPD-ITP than in other groups. However, having achieved response, there were no significant differences between the durable response of the groups. Forty-three patients (49·4%) experienced adverse events (mainly grade 1-2), the commonest being hepatobiliary laboratory abnormalities. There were 10 deaths in this case series, all of which were related to pre-existing medical conditions. In routine clinical practice, eltrombopag is effective and well-tolerated in unselected patients with ITP secondary to both immune and infectious disorders. However, the response rate in LPD-ITP is low.
metadata.dc.identifier.doi: 10.1111/bjh.14788
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.